Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells

Published:2019-09-04 Issue:7 Volume:121 Page:600-610
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Jette Nicholas R.,Radhamani Suraj,Arthur Greydon,Ye Ruiqiong,Goutam Siddhartha,Bolyos Anthony,Petersen Lars F.,Bose Pinaki,Bebb D. Gwyn,Lees-Miller Susan P.

Funder

Ohlson Research Initiative, Charbonneau Cancer Institute, Calgary, Alberta, Canada

Cancer Research Society

U.S. Department of Health & Human Services | NIH | National Cancer Institute

Gouvernement du Canada | Canadian Institutes of Health Research

Alberta Cancer Foundation/Engineered Air Chair in Cancer Research # 21202

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/s41416-019-0565-8.pdf

Reference70 articles.

1. Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N., Johnson, D. A., Richardson, T. B. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921 (2005).

2. Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913–917 (2005).

3. Lord, C. J., McDonald, S., Swift, S., Turner, N. C. & Ashworth, A. A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. DNA Repair 7, 2010–2019 (2008).

4. Ashworth, A. & Lord, C. J. Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?. Nat. Rev. Clin. Oncol. 15, 564–576 (2018).

5. Thomas, A., Murai, J. & Pommier, Y. The evolving landscape of predictive biomarkers of response to PARP inhibitors. J. Clin. Investig. 128, 1727–1730 (2018).

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chemo-Phosphoproteomic Profiling with ATR Inhibitors Berzosertib and Gartisertib Uncovers New Biomarkers and DNA Damage Response Regulators;Molecular & Cellular Proteomics;2024-08

2. SETD1A-dependent EME1 transcription drives PARPi sensitivity in HR deficient tumour cells;2024-06-17

3. Therapeutic Options Targeting the Ataxia-Telangiectasia Mutated (ATM)-mediated DNA Damage Response, Macropinocytosis, and Adaptive Immunity in Ovarian Cancer;Anticancer Research;2024-03-27

4. Clinical translation for targeting DNA damage repair in non-small cell lung cancer: a review;Translational Lung Cancer Research;2024-02

5. Elimusertib has anti-tumor activity in preclinical patient-derived pediatric solid tumor models;Molecular Cancer Therapeutics;2023-12-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3